Product image of Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated)) supplied by GNH India

Neisvac-C

Active Ingredient:
Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated)
Origin:
EU

Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated))

Tetanus toxoid, algeldrate, Neisseria meningitidis group C polysaccharide, the active ingredient in Neisvac-C, is a vaccine presented as a vaccine for intramuscular use. It is used to prevent tetanus and meningococcal disease caused by Neisseria meningitidis group C in individuals requiring immunization.

GNH India supplies Neisvac-C as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Pfizer S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Neisvac-C is a combined tetanus and meningococcal group C vaccine used to stimulate protective immunity against specific bacterial toxins and polysaccharides.

  • Tetanus: induces immunity against tetanus toxin, reducing the risk of tetanus infection.
  • Meningococcal group C disease: stimulates antibodies against the capsular polysaccharide of Neisseria meningitidis group C, preventing invasive disease.
  • Travel or outbreak immunization: administered as part of prophylactic schedules for travelers or during public health campaigns to control meningococcal group C outbreaks.

How It Works

  • Neisvac-C contains tetanus toxoid and de‑O‑acetylated polysaccharide from Neisseria meningitidis group C, combined with algeldrate as an adjuvant. After intramuscular injection, the toxoid and polysaccharide are taken up by antigen‑presenting cells, prompting a T‑cell‑dependent response that leads to production of high‑affinity antibodies against tetanus toxin and the meningococcal capsular antigen, establishing active immunity.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Low‑grade fever: transient temperature rise within 24‑48 hours.
  • Headache: mild headache following vaccination.
  • Fatigue or malaise: general feeling of tiredness.
  • Muscle aches: transient myalgia.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with progressive weakness.
  • Seizures: uncommon convulsive episodes.
  • Severe hypotension: marked drop in blood pressure post‑injection.
  • Persistent high fever: fever lasting more than 48 hours.
  • Severe local reaction: extensive necrosis or ulceration at the injection site.

Precautions & Warnings

Neisvac-C should be administered after careful assessment of the individual's health status.

  • Hypersensitivity screening: avoid in persons with known severe allergy to any vaccine component.
  • Acute illness deferment: postpone vaccination in individuals with moderate or severe febrile illness.
  • Post‑vaccination observation: monitor for at least 15 minutes for immediate reactions.
  • Immunocompromised caution: response may be reduced; consult healthcare provider.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Neisvac-C may interact with other immunological agents or therapies.

Major Interactions (Avoid)

  • Concurrent administration of other tetanus‑containing vaccines: may increase risk of hypersensitivity.
  • Live viral vaccines given within 4 weeks: may interfere with immune response.

Moderate Interactions (Monitor Closely)

  • Immunoglobulin therapy: can reduce vaccine efficacy if given within 2 weeks.
  • Immunosuppressive drugs: may diminish antibody production, requiring serologic monitoring.
  • Antipyretics taken prophylactically: may mask early signs of adverse reactions.

Frequently Asked Questions

Neisvac-C is a combined vaccine that provides protection against tetanus and meningococcal disease caused by Neisseria meningitidis group C. It is administered to individuals who need immunization against these bacterial infections, including travelers, children, and adults in endemic regions.

The tetanus toxoid component stimulates the immune system to produce antibodies that neutralize tetanus toxin, while the de‑O‑acetylated polysaccharide from meningococcal group C induces antibodies targeting the bacterial capsule. Together, they create active immunity that prevents infection by these pathogens.

The dosing schedule for Neisvac-C is determined by the prescribing healthcare professional based on age, vaccination history, and specific immunization guidelines. The prescriber will decide the number of doses and the interval between them.

Safety data for Neisvac-C in pregnancy and lactation are limited. The vaccine should only be used if the potential benefits outweigh any potential risks, and the decision should be made by a qualified healthcare provider after evaluating the individual’s circumstances.

To order Neisvac-C, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling), and import documentation.

Neisvac-C combines tetanus toxoid with a de‑O‑acetylated meningococcal group C polysaccharide, similar to other conjugate vaccines but without a protein carrier. Compared with conjugate formulations, it may have a slightly different immunogenic profile and storage requirements, but both aim to protect against the same diseases.

Neisvac-C must be stored refrigerated at 2‑8 °C. Keep the vials in the original packaging, protect them from light, and avoid freezing or shaking. Do not use the vaccine if it has been exposed to temperatures outside the recommended range.

Neisvac-C is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection should be performed by a qualified healthcare professional using aseptic technique.

The most serious risks include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and rare neurological events. Immediate medical attention is required if signs of a serious reaction, such as difficulty breathing, swelling of the face or throat, or rapid weakness, occur after vaccination.

Neisvac-C should not be given to individuals with a known severe allergy to any of its components, including tetanus toxoid, algeldrate, or the meningococcal polysaccharide. It is also contraindicated in persons who have experienced a serious reaction to a previous dose of the same vaccine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated)

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT